3 reasons I’m convinced GlaxoSmithKline is a great buy

GlaxoSmithKline plc’s (LON:GSK) rising revenues, merger announcement with Pfizer and recent softening in share price make it a worthwhile purchase for the long-term investor.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Minimising risk is a key priority for many investors and so it is always good to hold shares of companies in ‘defensive’ sectors in an investment portfolio. They provide the solid foundation during cyclical downturns that sectors with ‘discretionary’ demand – like luxury or retail – don’t as the latter suffer typically sharp dips.

Companies like the accounting software provider Sage Group and paper-based packaging provider Smurfit Kappa are good examples of defensive plays. Pharmaceuticals and consumer-healthcare major Glaxo SmithKline (LSE: GSK) is another such stock, which I reckon is a great buy right now. Here are three reasons why.

Splitting up to come together

For start, the company is at the beginning of a bold and highly interesting change – a split-up into two separate entities. One of these will focus on pharmaceuticals and vaccines and the other will concentrate on consumer healthcare.

And this is not all. The latter will merge with Pfizer to form what will likely be one of the largest companies in the sector across major markets. I really like the idea that GSK’s consumer healthcare business will get a big boost, and put it in a position of market leadership by a mile.  

Window of buying opportunity

A soon as the announcement hit the news in December last year, the share price rose sharply, by 3.8% compared to the previous day. A little over a month later, however, it has fallen back to pre-announcement levels. Which brings me to my second point: this is  a great time to buy this stock, especially since the company’s quarterly results are due soon, which could lead to another upswing in share price. If you are an investor who is focused on risk-aversion, I think GSK is worth considering.  

Of course, if you like the thrill of a bit of risk for some gain, you might want to wait for results day and ride the share price rollercoaster, especially so given the recent relation of the share price to results announcements. The price has fallen between 1% and 3.5% on three of the previous four results days in the past year, but has recovered quickly thereafter. That said, I wouldn’t focus too much on this point, given that for the Foolish investor who’s in it for the long haul, such short-term ups and downs are irrelevant.

Complete dependability

To assess GSK’s long-term investing potential, a look at the financials confirms that it is is a company with strong investor appeal. It has seen steady growth in revenues over the past few years and it continues to be profitable. Last but certainly not least, I cannot ignore the significance of this company as Brexit happens. Less than 30% of the companies’ revenues came from Europe in the last quarter, with the rest coming from the US and other international markets, helping to protect it from excessive exposure to a possibly-weaker UK or EU economy. I’d buy this share today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »